%0 Journal Article
%A Wagemann, Olivia
%A Brendel, Matthias
%A Franzmeier, Nicolai
%A Nübling, Georg
%A Gnoerich, Johannes
%A Zaganjori, Mirlind
%A Prix, Catharina
%A Stockbauer, Anna
%A Wlasich, Elisabeth
%A Loosli, Sandra V
%A Sandkühler, Katja
%A Frontzkowski, Lukas
%A Höglinger, Günter
%A Levin, Johannes
%T Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.
%J Frontiers in neuroscience
%V 18
%@ 1662-4548
%C Lausanne
%I Frontiers Research Foundation
%M DZNE-2025-00223
%P 1505999
%D 2025
%X Adults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five adults with DS (40
%K 18F-PI-2620 (Other)
%K Alzheimer (Other)
%K case series (Other)
%K down syndrome (Other)
%K tau PET (Other)
%K trisomy 21 (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39834700
%2 pmc:PMC11744071
%R 10.3389/fnins.2024.1505999
%U https://pub.dzne.de/record/276151